Antibody Fc receptor binding and T cell responses to homologous and heterologous immunization with inactivated or mRNA vaccines against SARS-CoV-2 von Cohen, Carolyn A., Leung, Nancy H. L., Kaewpreedee, Prathanporn, Lee, Kelly W. K., Jia, Janice Zhirong, Cheung, Alan W. L., Cheng, Samuel M. S., Mori, Masashi, Ip, Dennis K. M., Poon, Leo L. M., Peiris, J. S. Malik, Cowling, Benjamin J., Valkenburg, Sophie A.

Volltext

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma von Gibney, G.T., Aziz, S.A., Camp, R.L., Conrad, P., Schwartz, B.E., Chen, C.R., Kelly, W.K., Kluger, H.M.

Volltext

Efficacy of carboplatin–taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trials von Regan, M.M., O'Donnell, E.K., Kelly, W.K., Halabi, S., Berry, W., Urakami, S., Kikuno, N., Oh, W.K.

Volltext

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma von MCCAFFREY, J. A, HILTON, S, MAZUMDAR, M, SADAN, S, KELLY, W. K, SCHER, H. I, BAJORIN, D. F

Volltext

Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer von SABBATINI, P, LARSON, S. M, OUYANG, P, KELLY, W. K, SCHER, H. I, KREMER, A, ZHANG, Z.-F, SUN, M, YEUNG, H, IMBRIACO, M, HORAK, I, CONOLLY, M, DING, C

Volltext

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer von SCHER, H. I, KELLY, W. K

Volltext

Bicalutamide for advanced prostate cancer: the natural versus treated history of disease von SCHER, H. I, LIEBERTZ, C, KELLY, W. K, MAZUMDAR, M, BRETT, C, SCHWARTZ, L, KOLVENBAG, G, SHAPIRO, L, SCHWARTZ, M

Volltext

Pilot study of epothilone B analog (BMS-247550) and estramustine phosphate in patients with progressive metastatic prostate cancer following castration von Smaletz, O., Galsky, M., Scher, H. I., DeLaCruz, A., Slovin, S. F., Morris, M. J., Solit, D. B., Davar, U., Schwartz, L., Kelly, W. K.

Volltext

Clinical outcomes in men of diverse ethnic backgrounds with metastatic castration-resistant prostate cancer von Halabi, S, Dutta, S, Tangen, C M, Rosenthal, M, Petrylak, D P, Thompson, Jr, I M, Chi, K N, De Bono, J S, Araujo, J C, Logothetis, C, Eisenberger, M A, Quinn, D I, Fizazi, K, Morris, M J, Higano, C S, Tannock, I F, Small, E J, Kelly, W K

Volltext

Paclitaxel, Estramustine Phosphate, and Carboplatin in Patients With Advanced Prostate Cancer von KELLY, William Kevin, CURLEY, Tracy, GEORGE, Daniel, OH, William, SMITH, Matthew, KAUFMAN, Donald, SMALL, Eric J, SCHWARTZ, Lawrence, LARSON, Steve, TONG, William, SCHER, Howard, SLOVIN, Susan, HELLER, Glenn, MCCAFFREY, John, BAJORIN, Dean, CIOLINO, Allison, REGAN, Kevin, SCHWARTZ, Morton, KANTOFF, Philip

Volltext

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer von KELLY, W. K, SCHER, H. I, MADHU MAZUMDAR, VLAMIS, V, SCHWARTZ, M, FOSSA, S. D

Volltext

Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications von Ghossein, R A, Scher, H I, Gerald, W L, Kelly, W K, Curley, T, Amsterdam, A, Zhang, Z F, Rosai, J

Volltext

Clinical Trials in Relapsed Prostate Cancer: Defining the Target von Scher, Howard I., Mazumdar, Madhu, Kelly, William Kevin

Volltext

Histone deacetylases and cancer: causes and therapies von Marks, Paul A, Rifkind, Richard A, Richon, Victoria M, Breslow, Ronald, Miller, Thomas, Kelly, William K

Volltext

Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet von Armstrong, A.J., Antonarakis, E.S., Taplin, M.-E., Kelly, W.K., Beltran, H., Fizazi, K., Dahut, W.L., Shore, N., Slovin, S., George, D., Carducci, M.A., Corn, P., Danila, D., Dreicer, R., Heath, E., Rathkopf, D., Liu, G., Nanus, D., Stein, M., Smith, M.R., Sternberg, C., Wilding, G., Nelson, P.S., Halabi, S., Kantoff, P., Clarke, N.W., Evans, C.P., Heidenreich, A., Mottet, N., Gleave, M., Morris, M.J., Scher, H.I.

Volltext

Hormone-refractory (D3) prostate cancer: Refining the concept von Scher, Howard I., Steineck, Gunnar, Kevin Kelly, William

Volltext

Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial von BAJORIN, D. F, MCCAFFREY, J. A, HILTON, S, MAZUMDAR, M, KELLY, W. K, SCHER, H. I, SPICER, J, HERR, H, HIGGINS, G

Volltext

Endocrine Withdrawal Syndrome and Its Relevance to the Management of Hormone Refractory Prostate Cancer von Kelly, W.K.

Volltext

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer von KELLY, W. K, CURLEY, T, LEIBERTZ, C, DNISTRIAN, A, SCHWARTZ, M, SCHER, H. I

Volltext

Histone deacetylase inhibitors: from target to clinical trials von Kelly, William K, O'Connor, Owen A, Marks, Paul A

Volltext